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Abstract
Purpose
To establish an in vitro model that would mirror the in vivo corneal stromal environment in
diabetes (DM) patients.
Methods
Human corneal fibroblasts from Healthy (HCFs), Type 1DM (T1DM) and Type 2DM (T2DM)
donors were isolated and cultured for 4 weeks with Vitamin C stimulation in order to allow for
extracellular matrix (ECM) secretion and assembly.
Results
Our data indicated altered cellular morphology, increased cellular migration, increased ECM
assembly, and severe mitochondrial damage in both T1DM and T2DMs when compared to
HCFs. Furthermore, we found significant downregulation of Collagen I and Collagen V
expression in both T1DM and T2DMs. Furthermore, a significant up regulation of fibrotic
markers was seen, including α-smooth muscle actin in T2DM and Collagen III in both T1DM
and T2DMs. Metabolic analysis suggested impaired Glycolysis and Tricarboxylic acid cycle
(TCA) pathway.
Conclusion
DM has significant effects on physiological and clinical aspects of the human cornea. The
benefits in developing and fully characterizing our 3D in vitro model are enormous and might
provide clues for the development of novel therapeutics.
PLOS ONE | DOI:10.1371/journal.pone.0168845 December 22, 2016 1 / 17
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Priyadarsini S, Sarker-Nag A, Rowsey TG,
Ma J-X, Karamichos D (2016) Establishment of a
3D In Vitro Model to Accelerate the Development of
Human Therapies against Corneal Diabetes. PLoS
ONE 11(12): e0168845. doi:10.1371/journal.
pone.0168845
Editor: Alexander V. Ljubimov, Cedars-Sinai
Medical Center, UNITED STATES
Received: October 4, 2016
Accepted: December 7, 2016
Published: December 22, 2016
Copyright: © 2016 Priyadarsini et al. This is an
open access article distributed under the terms of
the Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper submitted.
Funding: This work was supported by the National
Eye Institute, EY020886 (DK), https://nei.nih.gov/;
National Eye Institute, P30EY021725 (Dr. Gene
Anderson), https://nei.nih.gov/.
Competing Interests: The authors have declared
that no competing interests exist.
Introduction
Diabetes mellitus (DM) is a common metabolic disease characterized by hyperglycemic condi-
tion that has a higher prevalence rate with increased number of cases every year[1,2]. Approxi-
mately 371 million people have been diagnosed with DM worldwide and the incidence rate is
expected to double by 2030[3–5]. In the United States it has also been termed as the epidemic
disease of an increasing age and obese population[1]. Approximately 6.2 million people are
underdiagnosed in the United States alone.
DM is broadly divided into two main categories: Type 1DM (T1DM) and Type 2DM
(T2DM). T1DM is known as “insulin dependent” or “juvenile-onset’ diabetes and caused due
to the autoimmune destruction of the β-cells in the pancreas, accounting for about 5–10% of
total DM cases worldwide[2,5,6]. T2DM, on the other hand, is known as “non-insulin depen-
dent” or “adult-onset” diabetes, caused by excessive elevated blood glucose levels that lead to
insulin resistance. T2DM accounts for about ~90–95% of total DM population [2,5,6].
Chronic hyperglycemic conditions during DM often lead to complications, damage, and fail-
ure of several different organs including the eyes, heart, nerves, kidney and blood vessel. The
most common ocular complications during DM include diabetic retinopathy, cataract, glau-
coma, ischemic optic neuropathy, cranial nerve palsies and recurrent corneal erosion syndrome
[7–11]. The cornea, in particular, is greatly affected with changes and defects that include recur-
rent corneal erosions, persistent epithelial defects, corneal endothelial damage, reduced corneal
sensitivity, increased corneal thickness, susceptibility to corneal trauma and alteration in tear
quality and quantity [7–9]. To date, studies on DM-related corneal defects, commonly known
as diabetic keratopathy, have been primarily focused on the epithelial layer and nerves that are
known for significant damages and deterioration [7–9,12,13]. These studies are mainly in vivo
with the exception of Dr. Ljubimov’s and co-authors model where cadaveric corneas are used to
study epithelial defects [13,14]. While these studies have significantly increased our knowledge
with regards to the pathophysiology of diabetic keratopathy, we are still lacking a good grasp of
understanding the molecular mechanism involved. As a result, any developed therapeutic
agents and protocols that have worked in rodents have failed in humans [15–17].
We have developed a stroma-like model that consists of primary human corneal fibroblasts
from healthy (HCF), T1DM, and T2DM donors that can mimic the stroma seen in vivo. In this
study, we investigated the morphological and molecular differences between healthy and dia-
betic self-assembled extracellular matrix (ECM). To the author’s knowledge, this is the first in
vitro model available which can be used to recapitulate the in vivo corneal stromal defects
resulted by diabetic keratopathy. Further studies of such a novel model may enable develop-
ment of novel therapeutics to treat corneal DM.
Materials and Methods
Ethics and inclusion criteria
Institutional review board approval was received prior to initiation of experiments described
in this study (#4509). All parts of the study met the tenets of the Declaration of Helsinki. Cor-
neal samples were obtained from the National Development and Research Institute (NDRI)
and the Oklahoma Lions Eye Bank. Inclusion criteria for the diabetic donors included clinical
diagnosis of Type 1 or 2 diabetes and absence of other unrelated diseases or ocular pathology.
The control group included corneas isolated from cadavers with no history of ocular trauma
or systemic diseases (Table 1). The causes of death for the diabetic groups were considered to
be diabetic-related complications (acute cerebral infarction, cerebrovascular accident, compli-
cations from end stage renal disease, respiratory failure) with the cause of death for healthy
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controls varying from accidental to non-diabetic related diseases (Blunt force trauma, head
trauma, end stage renal disease, acute segment elevation myocardial infarction, subarachnoid
hemorrhage, cardiac arrest). In this study a total of 16 diabetic donors’ corneal samples (8
donors for each T1DM and T2DM with a total of 4 males and 4 females in each group) and 8
healthy control samples (5 males and 3 females) were analyzed. The average age range for each
group was as follows: (Healthy) 57.7±5.8 years, (T1DM) 55±6.8 years, and (T2DM) 59.14±4.94
years. The duration of diabetes was from 3–30 years (with a mean of 15.71±4.17 years)
(Table 1).
Primary culture of healthy and diabetic corneal fibroblast cells
HCF, T1DM and T2DM cells were isolated and cultured in Eagle’s Minimum Essential
Medium (American Type Culture Collection, Manassas, VA, USA) containing 10% fetal
bovine serum (Atlantic Biologicals, Miami, FL, USA) and 1% antibiotic (Life Technologies,
Grand Island, NY, USA) [18–21]. The cultures were passed upon 80–100% confluence follow-
ing previously optimized protocols [18–21].
Assembly of 3D constructs
3D constructs for HCFs, T1DM, and T2DM cells were prepared as previously described
[18,19,21,22]. Briefly, 1 × 106 cells/well were seeded on polycarbonate membrane inserts with
0.4-μm pores (Corning Costar; Corning Incorporated, Corning, NY, USA) and cultured in
Eagle’s Minimum Essential Medium containing 10%fetal bovine serum and 1% antibiotic and
stimulated with 0.5 mM 2-O-α-Dglucopyranosyl-L-ascorbic acid (American Custom Chemi-
cals Corporation, San Diego, CA, USA). Cultures were maintained for 4 weeks and fresh
media was supplied every other day during the entire study period.
Real-time PCR
mRNA expression of our samples was evaluated by qRT-PCR as previously described
[20,22,23]. Total RNA was extracted using Ambion RNA mini extraction kit (Ambion TRIzol
Plus RNA Purification Kit: Life technologies, Carlsbad, CA) followed by cDNA synthesis using
SuperScript III First-Strand Synthesis SuperMix (Invitrogen, Carlsbad, CA) as per manufac-
turer’s protocol. TaqMan gene expression of (Applied Biosystems, Foster City) GAPDH
(Hs99999905_m1) and 18S (Hs99999901_s1) was used as our controls. ACTA2
(Hs00426835_m1), COL1A1 (Hs00164004_m1), COL3A1 (Hs00943809_m1), COL5A1
(Hs00609133_m1), IGF1 (Hs01547654_m1) and IGF1R (Hs00609566_m1) were investigated
(Table 2). Data analysis was performed using Graph Pad Prism 6 and MS-Excel.
Western blot analysis
Cell lysates were used for western blot analysis, as per our previously optimized protocol
[20,24]. Preparation of cell lysates was initiated by using RIPA buffer (50 mM Tris, pH 8, 150
Table 1. Characteristics of study population
Healthy Controls T1DM T2DM
Donors (n) 8 8 8
Range(years)/Mean Age 30-76/57.71429 23-70/55 40-73/59.14286
Sex (male/female) (n) 5/3 4/4 4/4
Diabetics duration range - 3–28 4–30
doi:10.1371/journal.pone.0168845.t001
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mM NaCl, 1% Triton X-100, 0.1% SDS, 1% sodium deoxycholate) containing protease and
phosphatase inhibitors (Sigma Aldrich; St. Louis, MO) followed by brief incubation, centrifu-
gation and stored at -20˚C until further usage. Equal amounts of proteins were loaded on to
4%–20% Tris-Glycine gels (Novex, Life technologies, Carlsbad, CA) for gel electrophoresis fol-
lowed by protein transfer to a nitrocellulose membrane (Novex, Life Technologies) and further
incubation in 5% BSA blocking solution (Thermo Scientific). The membranes were then incu-
bated with primary antibodies (Table 3): anti-Collagen I (ab34710; Abcam; Cambridge; MA),
Collagen III (ab7778; Abcam; Cambridge; MA), Collagen V (ab94673; Abcam; Cambridge;
MA), α-smooth muscle actin (ab5694; Abcam; Cambridge; MA), IGF1(Cambridge; MA),
1GF1R (Abcam; Cambridge; MA), glyceraldehyde 3-phosphate dehydrogenase (GAPDH,
ab9485; Abcam; Cambridge; MA) (Table 3). Antibodies were used at 1:1000 dilution in TBST
overnight at 4˚C with rocking followed by washing of the membranes and incubation with a
secondary antibody (Alexa Flour1 568 Donkey anti-Rabbit, IgG [H+L], Abcam) at 1:2000
dilutions for 1 hr. UVP imaging system was used for band detection and quantification by
densitometry. Net intensities were normalized to the loading control (GAPDH) and depicted
as fold change.
Immunofluorescence
The constructs were processed for cytochemical analysis by fixing with 4% paraformaldehyde
in PBS [18,22,25,26]. This was followed by sample permeabilization with PBS containing
0.25% Triton X-100 (Sigma-Aldrich, St. Louis, MO, USA) and blocking with 1% BSA (Thermo
Scientific) in PBST (0.05% Tween 20 (Sigma-Aldrich, St. Louis, MO, USA) PBS) containing
0.3 M glycine (Fischer Scientific,). Samples were incubated with Alexa Flour Phalloidin (Life
Technologies, USA) primary antibody overnight at 4˚C and stained with DAPI (1μg/ml, Life
Technologies, USA). The samples were imaged using confocal microscope (Olympus Confocal
FV 500, USA).
Table 2. RT-PCR probes and their dilutions
Probes Catalogue No#1 Final concentration Company
GAPDH Hs99999905_m1 1X Life technologies
18S Hs99999901_s1 1X Life technologies
ACTA2 Hs00426835_m1 1X Life technologies
COL1A1 Hs00164004_m1 1X Life technologies
COL3A1 Hs00943809_m1 1X Life technologies
COL5A1 Hs00609133_m1 1X Life technologies
IGF1 Hs01547654_m1 1X Life technologies
IGF1R Hs00609566_m1 1X Life technologies
doi:10.1371/journal.pone.0168845.t002
Table 3. Western Blot antibodies and their dilutions
Antibody Catalogue No# Dilution Company
Anti-Collagen I ab34710 1/1000 Abcam
Anti-Collagen III ab7778 1/1000 Abcam
Anti-Collagen V ab94673 1/1000 Abcam
Alpha-smooth muscle actin ab5694 1/1000 Abcam
Insulin Growth Factor 1(IGF1) ab9572 1/1000 Abcam
Insulin Growth Factor Receptor 1 ab131476 1/1000 Abcam
Anti-GAPDH ab9485 1/1000 Abcam
doi:10.1371/journal.pone.0168845.t003
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Cell migration and proliferation assay
Cell migration was assessed using the in vitro scratch assay model [27]. Briefly, 1×106 cells/well
for all three cell types (HCFs, T1DM and T2DM) were seeded in six well plates and allowed to
attain 100% confluency. Scratches were performed using a sterile micropipette tip through the
cell monolayer and washed with PBS after the scratch was made. This was followed by adding
fresh medium to the culture plates and then imaging the wounded site at predetermined time
points (0hr, 4hr, 24hr and 48hr). The migration pattern was evaluated and quantified using
ImageJ software.
Cellular proliferation was measured using vybrant MTT cell proliferation assay kit (Life
Technologies, USA). About 1× 105 cells/well was seeded and after 24 hours of culture 10μl
of the 12mM MTT stock solution was added to each well and incubated for another 3–4
hours at 37˚C as per the manufacturer’s protocol. Thereafter, 100μl of the SDS-HCl solution
was added to each well and evenly mixed, followed by a brief incubation for about 4 hours
at 37˚C in a humidified chamber. Samples were mixed again and the absorbance was mea-
sured at 570nM using the plate reader. The results were analyzed and processed in Excel
and Graph Pad Prism 6 (GraphPad Software, CA) to determine the cellular proliferation
rate.
Transmission Electron microscopy and mitochondrial quantification
All 3D constructs were fixed with 4% Paraformaldehyde and 2% Glutaraldehyde in 0.1M
Sodium Cacodylate buffer for 6 days at 4˚C. Samples were further post fixed in 1%
Osmium tetroxide in Sodium Cacodylate, and rinsed with 0.1M Sodium Cacodylate
buffer. Following previously reported methods [18,22,28,29] samples were embedded in
resin plus BDMA (accelerator) and polymerized at 60˚C for 48 hours. Ultrathin sections
were stained with Lead Citrate and Uranyl Acetate before viewing on a Hitachi H7600
Transmission Electron Microscope at 80 kV equipped with a 2k x 2k AMT digital camera.
Mitochondrial structure was imaged and quantified. Normal mitochondrial structure was
defined as clear double membrane, discrete cristae and little internal space. The number
of mitochondria that did not exhibit the normal mitochondrial structure were plotted and
quantified.
Metabolomics
The samples were prepared as per previously optimized protocol [30–32]. Briefly, samples
were washed with 1xPBS, lysed with ice-cold 80% methanol, incubated briefly on dry ice for
about 15 minutes and then homogenized for ensuring complete cell lysis. Isolated metabolites
were stored at -80˚C until further processing. CIMminer was used to analyze the metabolo-
mics data which was available from the genomics and bioinformatics group (http://discover.
nci.nih.gov/cimminer/home.do) for generating a color-coded Clustered Image Map (CIM).
For all the metabolites, the raw net intensity data present in at least n = 3 were input into the
freely available software for generating a one matrix CIM. All the metabolites were clustered
according to abundance.
Statistical Analysis
Statistical analysis was conducted using Graph Pad Prism 6 and a one-way ANOVA and
Mann-Whitney unpaired T-test, where appropriate. P<0.05 was considered statistically
significant.
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Results
ECM and cellular morphology in T1DM and T2DM
We have previously reported that HCFs cultured in Vitamin C on transwell polycarbonate
membranes lead to multi-layer, highly organized 3D construct [18,19,21–23,29,33]. In this cur-
rent study, we extended our expertise to develop those 3D constructs using T1DM and T2DM
primary human corneal cells. Fig 1A–1C shows representative images of cells stained with
Phalloidin (red) and DAPI (blue).
Both our T1DM and T2DM constructs (Fig 1) showed significant increase in thickness (4.5
fold; p0.0001 and 4 fold; p0.0001 respectively) when compared to HCFs (Fig 1D). In addi-
tion, there was a significant increase in cells per unit area (mm2) in both T1DM and T2DM
(Fig 1E) when compared to HCFs, indicating higher proliferation rates.
Cellular migration and proliferation
Studies have already shown hyperglycemic conditions often accelerates cellular proliferation
[34–37]. We analyzed and quantified cell migratory pattern for all the three cell types following
Fig 1. Confocal microscopy showing cellular morphology of HCFs, T1DMs, and T2DMs when cultured in our 3D constructs. (A-C) Representative
images of HCFs, T1DMs, and T2DMs stained with Phalloidin (red) and DAPI (blue). (A) HCF cells morphology showed uniform fibril diameter with regular
spacing. (B) T1DM cells showed thin fibril morphology with no interfibrillar spacing. (C) T2DM cells morphology also showed lack of fibrils organization and
arrangement. (D) Quantification of the construct thickness in HCFs, T1DMs, and T2DMs. (E) Cells per unit area (mm2) in HCFs, T1DMs, and T2DMs. For
all the three cell types a minimum of 4 confocal z-stack images were used, which were averaged, plotted and analyzed by Graph Pad Prism 6 software.
Error bars represent standard error of the mean. One-way ANOVA was performed (* = p0.05; ** = p0.01; *** = p0.001; **** = p0.0001).
doi:10.1371/journal.pone.0168845.g001
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the observation of increased ECM assembly (Fig 1). Using in vitro scratch assay model (Fig 2)
we observed significant increased cellular migration of 4 fold (p0.0001) in both T2DM (Fig
2C and 2D) and T1DM constructs (Fig 2B and 2D) when compared to HCFs (Fig 2A and 2D).
These data suggest that the ECM secreted by DM cells is altered in a way that promotes hyper
cellular migration.
Furthermore, we tested cellular proliferation using MTT assay, as shown in Fig 2E.
T1DMsshowed almost a 3 and 2 fold upregulation when compared to HCFs and T2DMs
respectively.These findings did not reach significance, but suggest a trend for increased cell
proliferation.
mRNA expression of secreted collagens by T1DM, T2DM and HCFs
We performed qRT-PCR to investigate Col I, Col III, and Col V expression by HCFs, T1DMs,
and T2DMs. Significant downregulation by 4 fold (p0.0001) in Col I expression was seen in
both T1DM and T2DMs when compared to HCFs (Fig 3A). Similarly, in T1DMs Col V
expression was decreased by 3 fold (p0.001) and by 4 fold (p0.0001) in T2DMs (Fig 3C).
Surprisingly, Col III regulation did not reach significance; although the trend was similar to
both T1DM and T2DMs expressing higher levels of Col III by at least 2 fold (Fig 3B).
The data was also plotted and examined as Col I/Col III and Col I/Col V ratios. Col I/Col
III ratio was 4 fold (p0.0001) downregulated in T1DMs and 4.5 fold (p0.0001) downregula-
tion in T2DMs. No significant difference was observed in Col I/Col V ratio in any of the cell
types/constructs. Overall, this data indicated that the constructs with T1DM and T2DM cells
were progressively becoming more fibrotic.
Protein level Collagen expression by T1DM, T2DM and HCFs
Protein levels were also examined for all three cell types. While complete agreement with
mRNA data is ideal, differences are not unusual, mainly attributed to the temporal effects
Fig 2. Scratch wound healing and MTT assay. (A-C) HCF, T1DM and T2DM cells were scratched and the
relative cell migration distance was quantified at 0hr, 4hr, 24hr and 48hr time points. (D) Scratch assay
quantification showing significant increase in cell migration distance in both T1DM and T2DMs when compared to
HCFs. (E) MTT assay quantification for HCF, T1DM, and T2DMs. Data was normalized to HCFs and fold regulation
is plotted. One way ANOVA for total n3 data sets. (* = p0.05; ** = p0.01; *** = p0.001; **** = p0.0001).
doi:10.1371/journal.pone.0168845.g002
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involved in mRNA expression that may not reflect protein expression at the functional level
[38]. In post-transcriptional modification where correlation between mRNA and protein
expression primarily depends upon the type of cell and the gene that is regulated [39].
Expression of Col I was significantly downregulated in both T1DM and T2DM cells, when
compared to HCFs, by 2.5 fold (p0.01) in T1DMs and 1.5 fold (p0.05) in T2DMs. No sig-
nificant difference in Col V expression was observed in HCF, T1DM or T2DMs (Fig 4C). Fur-
thermore, we did not observe any significant differences in Col III expression. When collagen
ratios were examined, T1DM showed significant downregulation (p0.05) in Col I/Col III
ratio (Fig 4D) whereas T2DM cells showed significant upregulation (p0.05) when compared
to the HCFs. There was also significant difference (~3 fold; p0.001) between the T1DM and
T2DM cells Col I/Col III ratio.
α- SMA, IGF1 and IGF1R expression by T1DM, T2DM and HCFs
We further assessed cellular differences by examining the expression of the fibrotic marker α-
SMA and key mediators in DM Insulin growth factor-1 (IGF1) and its receptor (IGF1-R). Our
data showed significant upregulation (p0.01) in α- SMA gene expression in T2DMs when
compared to the HCFs (Fig 5A). α- SMA expression between T1DM and T2DM constructs
was also found to be significantly regulated by 1.5 fold (p0.05; Fig 5A). No significant differ-
ence was observed in α- SMA at the protein level (Fig 5D). Despite the role of IGF-1 and IGF-
1R in DM we did not observe any significant changes either one of them at mRNA (Fig 5B and
5C) or protein levels (Fig 5E and 5F). These results suggest that IGF1and IGF1R activity might
be transient in the human diabetic keratopathy.
Fig 3. mRNA expression for (A) Col I, B) Col III, C) Col V, D) Col I/Col III ratio, and E) Col/Col V ratio, in
HCFs, T1DMs, T2DMs.(A-E) Quantification of gene expression and their ratios that are normalized to the loading
control. n7 for HCFs, T1DMs and T2DMs. Error bars represent standard error of the mean. One-way ANOVA was
performed (* = p0.05; ** = p0.01; *** = p0.001; **** = p0.0001).
doi:10.1371/journal.pone.0168845.g003
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Altered metabolic profile of T1DM and T2DM cells
The metabolic profiles of all 3D constructs were examined. Our study showed differential reg-
ulation for most of the key metabolites along the glycolytic pathway (Fig 6). Specifically, we
observed changes in metabolites expression from the very first step of glycolysis where glucose
gets converted to glucose-6-phosphate in both T1DM and T2DMs when compared to HCFs
(Fig 6). Fructose-6-phosphate is the second step of the pathway and it was found to be signifi-
cantly downregulated in T1DMs (p0.05) (Fig 6) when compared to HCFs. Fructose-6-phos-
pahte is formed due to rearrangement of Glucose 6-phosphate and this step is a reversible
process during normal condition of a cell. Fructose-1,6-bisphosphate was also downregulated
in T1DMs (p0.05) when compared to both HCF and T2DMs. Significant downregulated
expression of Dihydroxyacetone phosphate (2.5 folds p 0.01) was witnessed in both T1DM
and T2DMs when compared to our controls. Furthermore, Glyceraldehyde 3-phosphate
showed significant downregulation by 3.5 fold (p0.001) in T1DMs and by 2 folds (p0.01)
in T2DMs when compared to our healthy controls (Fig 6). 1, 3 Bisphosphoglycerate also
showed downregulated expression in both T1DM and T2DM cells whereas 3-Phosphoglycer-
ate was seen significantly upregulated (p0.05) in both the diabetic cell types (Fig 6). Clearly,
tight regulation of the glycolysis pathway is essential for normal cellular metabolism. Our data
suggests that both T1DM and T2DMs are metabolic dysregulated.
TCA cycle is another essential metabolic pathway which takes place inside the mitochon-
dria of the cells and provides energy for normal functioning of the body [40–43]. Acetyl-CoA
serves as the initial substrate for the TCA cycle, end products of glycolysis and pyruvate under-
goes conversion and leads to the formation of acetyl-CoA. Citrate and succinate are among the
vital metabolites along the TCA cycle. Citrate was significantly downregulated in T1DM (2
Fig 4. Protein expression for (A) Col I, B) Col III, C) Col V, D) Col I/Col III ratio, and E) Col/Col V ratio, in
HCFs, T1DMs, T2DMs.(A-E) Quantification of protein bands and their ratios that are normalized to the loading
control. And, n7 for HCFs, T1DMs and T2DMs. Error bars represent standard error of the mean. One-way
ANOVA was performed (* = p0.05; ** = p0.01; *** = p0.001; **** = p0.0001).
doi:10.1371/journal.pone.0168845.g004
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folds p0.01) and T2DM (3 folds p0.001; Fig 7) whereas no difference was observed in iso-
citrate. Malate was also significantly downregulated in T2DM cells (3.5 folds p0.0001) when
compared to both HCFs and T1DM cells (Fig 7). Overall, like the glycolysis pathway, these
results suggest significant dysregulation of the TCA cycle in both T1DM and T2DMs.
Structural mitochondrial damage
Given the metabolic dysfunctions observed, we examined the mitochondrion structure while
cultured in the 3D ECMs (Fig 8). We observed significant changes in mitochondrion morphol-
ogy in all three cell types. Smaller mitochondrial structures in both T2DM (Fig 8C) as well as
in T1DM (Fig 8B) were observed when compared to our healthy HCFs (Fig 8A). In T2DMs,
the mitochondrial structures are usually smaller, which has been reported through various
studies in skeletal muscle cells [40,41,44,45]. T1DMs (Fig 8B) had severe cellular mitochon-
drial damage with approximately 70% of the cells exhibiting some degree of abnormal struc-
ture and morphology (p 0.0001; Fig 8D). T2DM (Fig 8C) cells also showed mitochondrial
damage, to a lesser extent, with 30% of the cells damaged (p 0.05; Fig 8D).
Discussion
Diabetic keratopathy is one of the most common ophthalmic complications witnessed in a
vast majority of DM patients [8,9,46,47] and several other corneal dysfunctions. This is mainly
due to the fact that DM involves increases in corneal thickness [48–50], reduced corneal sensi-
tivity, corneal epithelial lesions[9,46], delayed wound healing capacity and repair mechanism
[51–54], and weakening of the epithelial barrier[55] leading to corneal infections and stromal
Fig 5. mRNA expression for A) α-SMA, B) IGF1 and C) IGF1R in HCFs, T1DMs, and T2DMs. Protein
expression for D) α-SMA, E) IGF1 and F) IGF1R in HCFs, T1DMs, and T2DMs. (A-C)Quantification of gene
expression and (D-E) quantification of protein bands normalized to HCFs where n7 for HCFs, T1DMs and T2DMs.
Error bars represent standard error of the mean. One-way ANOVA was performed (* = p0.05; ** = p0.01;
*** = p0.001; **** = p0.0001).
doi:10.1371/journal.pone.0168845.g005
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fibrosis[56,57]. Other complications that have been known to be associated with DM includes
but not limited to corneal nerve damage and endothelial dysfunction [58]. A diabetic patient’s
prolonged exposure to hyperglycemic environment often leads to toxic end product deposi-
tions at the basement membrane which results in cell death, opacity and eventually leads to
vision impairment [7,8,55,59,60] and various other ophthalmic complications.
The common treatment for treating corneal diabetes often involves corneal transplantation,
corneal surgery, and inhibitor treatment and in some cases contact lenses are also prescribed
[37]. However, these treatments are often not effective, mainly due to delayed wound healing
in diabetics which can adversely affect the repair mechanisms of the cornea [1,7,49]. Several
studies have been focused on developing various animal models that can help better under-
standing of the disease and also find proper treatment for DM, but treatments on these animal
models have not proven to be very effective, and their value to humans has not been verified.
Therefore, better understanding of corneal DM is necessary in order to discover and develop
novel therapeutic targets.
In our current study, we attempted to stimulate corneal stromal cells derived from donors
with DM to secrete and deposit their own organized ECM in a 3D culture model. In vivo, the
stroma makes up approximately 90% of the corneal thickness and is composed of ECM and
cells [21,33,61–63]. The ECM is made of exquisitely aligned and organized collagen, such as
types I and V [18,21,61,64]. These collagens, along with various proteoglycans, are critical for
the integrity and tensile strength of the stroma. Both Col I and V were present in our cultures
in HCF as well as T1DM and T2DM constructs, indicating their ability to self-assemble an
ECM with components similar to that found in the human stroma. Interestingly, both Col I
and V mRNA levels were downregulated in T1DM and T2DM, as compared to HCFs
Fig 6. Schematic representation and quantification of the metabolic flux modulation in glycolysis cycle
for HCFs, T1DMs, and T2DMs, when cultured in our 3D model. Quantification of metabolites activity expressed
along the glycolysis cycle. One way ANOVA was performed for total n4 data sets (* = p0.05; ** = p0.01;
*** = p0.001; **** = p0.0001).
doi:10.1371/journal.pone.0168845.g006
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indicating some level of dysfunction. Col III protein levels, which is associated with corneal
fibrosis [18,19,21,23,33,61,64,65], was instead upregulated by T1DM and T2DM pointing
Fig 7. Schematic representation and quantification of the metabolic flux modulation in TCA cycle for HCFs,
T1DMs, and T2DMs, when cultured in our 3D model. Quantification of metabolites activity expressed along the
TCA cycle One way ANOVA was performed for total n4 data sets (* = p0.05; ** = p0.01; *** = p0.001;
**** = p0.0001).
doi:10.1371/journal.pone.0168845.g007
Fig 8. TEM image showing mitochondrial structure in HCFs, T1DMs, and T2DMs, when cultured in our 3D model. (A) HCFs: Mitochondria
appeared normal, with a double membrane, discrete cristae and little internal space. (B) T1DMs: Mitochondria appeared condensed and showed
expanded internal spaces. (C) T2DMs: Smaller mitochondrial structure, dilated vacuoles and presence of endoplasmic reticulum were witnessed.
(D) Quantification analysis of abnormal mitochondria cells percentage in HCF, T1DM, and T2DM constructs. The data is representative of 4
independent experiments, n = 4 (* = p0.05; ** = p0.01; *** = p0.001; **** = p0.0001). Scale bars = 500nm.
doi:10.1371/journal.pone.0168845.g008
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towards a more fibrotic ECM been assembled. The correlation between mRNA and protein in
human cells is known to be notoriously poor and it depends on various biological factors. It is
unclear at this stage which is a more important finding between mRNA and protein expression
for the human DM cornea. Future generation studies will aim to address this important
question.
Furthermore, we determined the cell migratory properties of these cells, which is one of the
crucial factors that determines effective wound healing and normal function of the cornea. It is
usually directed by the interplay between various signal transduction pathways involving lipid
second messengers, small GTPases, kinases, cytoskeleton-modifying proteins, and motor pro-
teins[66]. In general, the fibroblast which essentially plays a vital role during wound healing
both in vivo and in vitro often migrates to the wounding site and thereby initiates secretion of
ECM proteins and effective cellular proliferation. Studies have shown that fibroblasts tend to
move at a slower pace and thereby often changes their migratory direction[67]. In cornea, cel-
lular migration which is a complex process and any deficiencies along this process can lead to
either impairment and various abnormal states such as chronic inflammation, developmental
defects, cancer invasion and metastasis[66]. In this study, we found significantly higher cell
migration in both T1DM and T2DMs when compared to the HCFs. In agreement with what is
seen in vivo, this suggests altered cellular processes that often lead to the secretion of aberrant
ECM components.
We have previously identified several key metabolites that play a significant role during the
initiation of corneal stromal defects and which clearly distinguish the differences in corneal
cells derived from healthy individuals to that of the diseased ones. Not surprisingly, several
metabolites were differentially regulated in both T1DM and T2DM constructs when compared
to HCFs. It is already known that DM, [68,69] is associated with glucose metabolism dysfunc-
tion. Glycolysis and TCA cycle are the two most important cellular metabolic pathways that
are used by the cells to generate energy for driving various bio-chemical reactions [31]. Alter-
ations in these metabolic cycles can be critical in diabetic keratopathy. Our data shows that
several key metabolites of both pathways were significantly altered which highlights the impor-
tance of our 3D in vitro model and validates its accuracy.
To further highlight the damage maintained by T1DM and T2DMs, we investigated the
mitochondrial structural profiles of these cell types while cultured in our 3D model. Mitochon-
drial dysfunction has been widely associated with altered cellular metabolism [41,42,45,70].
The loss of mitochondrial function and integrity has often been found to lead to various patho-
logical conditions and diseases including diabetes, cardiovascular disorders, neurodegenera-
tive disorders and different eye related diseases [71–73]. Unfortunately, not much information
is available on the role of mitochondrial dysfunction with regards to diabetic keratopathy.
Here, we report significant differences in mitochondrial structure in both T1DM and T2DMs,
as compared to HCFs, when allowed to secrete and assembly their own ECM. These findings
are in agreement with previous reports in the human corneal stroma showing that mitochon-
drial dysfunction [71] leads to collapsed inner mitochondrial membranes that may inhibit or
activate the mitochondrial electron transport chain potential.
Corneal defects have been reported in both T1DM and T2DM patients, but the exact patho-
physiological differences (if any) between the two is largely unknown. Future studies will aim
to adress this and hope to pave the way for the devlopment of targeted therapeutics.
It is truly remarkable how both T1DM and T2DMs can maintain, at least partially, their
inherent defects following in vitro expansion. Given the direct interplay of the corneal stroma
and the nerve network we believe that key players to the regulation of the corneal DM defects
exist in the stroma layer and the resident keratocytes/fibroblasts. Understanding the pheno-
type and characteristics of the human DM cornea stroma as well as the cells that reside within
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it is critical. We believe that our novel 3D model can dissect crucial aspects of the diabetic kera-
topathy pathology and pave the way for the development of new therapeutics.
Conclusion
We strongly believe that our in vitro model will help our efforts to delineate the molecular
mechanisms of the human diabetic keratopathy and pave the way for better understanding of
the corneal stromal defects due to DM. Further development of this model should provide
important clues to the development of novel therapeutics to treat diabetic keratopathy defects.
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